Navana Pharmaceuticals PLC (DSE:NAVANAPHAR)
Bangladesh
· Delayed Price · Currency is BDT 58.30
-0.50 (-0.85%)
At close: Apr 28, 2026
Navana Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 |
| Revenue | 10,073 | 8,843 | 6,898 | 5,706 | 4,759 | 3,607 | Upgrade
|
| Revenue Growth (YoY) | 26.26% | 28.19% | 20.89% | 19.91% | 31.95% | 14.53% | Upgrade
|
| Cost of Revenue | 5,717 | 4,965 | 3,770 | 3,110 | 2,599 | 1,993 | Upgrade
|
| Gross Profit | 4,356 | 3,878 | 3,128 | 2,596 | 2,160 | 1,614 | Upgrade
|
| Selling, General & Admin | 2,838 | 2,432 | 2,136 | 1,841 | 1,591 | 1,265 | Upgrade
|
| Operating Expenses | 2,838 | 2,432 | 2,136 | 1,841 | 1,591 | 1,265 | Upgrade
|
| Operating Income | 1,518 | 1,446 | 991.84 | 755.72 | 569.6 | 348.59 | Upgrade
|
| Interest Expense | -638.08 | -726.63 | -463.57 | -234.89 | -200.42 | -75.18 | Upgrade
|
| Interest & Investment Income | 0.36 | 1.07 | 1.47 | 5.84 | 5.58 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -56.46 | -54.08 | -25.18 | -33.38 | -93.98 | -2.52 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.56 | 6.15 | 11.39 | -1.91 | 27.64 | 30.47 | Upgrade
|
| EBT Excluding Unusual Items | 830.51 | 672.48 | 515.95 | 491.38 | 308.42 | 301.39 | Upgrade
|
| Gain (Loss) on Sale of Investments | -14.8 | -10.46 | -0.88 | -42.3 | 82.9 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.16 | -0.09 | 1.18 | - | 0.47 | 1.02 | Upgrade
|
| Pretax Income | 819.53 | 661.93 | 516.25 | 449.08 | 391.79 | 302.41 | Upgrade
|
| Income Tax Expense | 210.49 | 174.12 | 111.62 | 92.14 | 117.78 | 100.12 | Upgrade
|
| Net Income | 609.04 | 487.81 | 404.63 | 356.94 | 274 | 202.29 | Upgrade
|
| Net Income to Common | 609.04 | 487.81 | 404.63 | 356.94 | 274 | 202.29 | Upgrade
|
| Net Income Growth | 44.40% | 20.56% | 13.36% | 30.27% | 35.45% | 47.23% | Upgrade
|
| Shares Outstanding (Basic) | 107 | 107 | 107 | 99 | 80 | 80 | Upgrade
|
| Shares Outstanding (Diluted) | 108 | 107 | 107 | 99 | 80 | 80 | Upgrade
|
| Shares Change (YoY) | 0.45% | - | 8.05% | 23.91% | - | - | Upgrade
|
| EPS (Basic) | 5.67 | 4.54 | 3.77 | 3.59 | 3.42 | 2.52 | Upgrade
|
| EPS (Diluted) | 5.65 | 4.54 | 3.77 | 3.59 | 3.42 | 2.52 | Upgrade
|
| EPS Growth | 43.80% | 20.56% | 4.92% | 5.13% | 35.45% | 47.23% | Upgrade
|
| Free Cash Flow | 2,071 | 1,444 | -625.1 | -1,404 | -1,160 | -399 | Upgrade
|
| Free Cash Flow Per Share | 19.19 | 13.44 | -5.82 | -14.13 | -14.45 | -4.97 | Upgrade
|
| Dividend Per Share | 1.400 | 1.400 | 1.400 | 1.300 | 1.100 | - | Upgrade
|
| Dividend Growth | - | - | 7.69% | 18.18% | - | - | Upgrade
|
| Gross Margin | 43.25% | 43.85% | 45.34% | 45.50% | 45.39% | 44.75% | Upgrade
|
| Operating Margin | 15.07% | 16.35% | 14.38% | 13.24% | 11.97% | 9.66% | Upgrade
|
| Profit Margin | 6.05% | 5.52% | 5.87% | 6.25% | 5.76% | 5.61% | Upgrade
|
| Free Cash Flow Margin | 20.55% | 16.33% | -9.06% | -24.61% | -24.37% | -11.06% | Upgrade
|
| EBITDA | 1,804 | 1,715 | 1,163 | 966.13 | 675.37 | 397.71 | Upgrade
|
| EBITDA Margin | 17.91% | 19.39% | 16.86% | 16.93% | 14.19% | 11.03% | Upgrade
|
| D&A For EBITDA | 285.64 | 268.77 | 171.25 | 210.41 | 105.77 | 49.12 | Upgrade
|
| EBIT | 1,518 | 1,446 | 991.84 | 755.72 | 569.6 | 348.59 | Upgrade
|
| EBIT Margin | 15.07% | 16.35% | 14.38% | 13.24% | 11.97% | 9.66% | Upgrade
|
| Effective Tax Rate | 25.68% | 26.30% | 21.62% | 20.52% | 30.06% | 33.11% | Upgrade
|
| Advertising Expenses | - | 42.15 | 38.4 | 33.13 | 80.86 | 19.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.